End-to-End Analytics for a Complex Cross-Border Pharmaceutical Acquisition
A global pharmaceutical company required rigorous Quality of Earnings and commercial due diligence support for a $1B+ cross-border acquisition. The engagement demanded rapid analytics buildout across multiple product lines, geographies, and revenue streams — under significant deal timeline pressure.
I led the analytics workstream end-to-end: designing the analytical framework, coordinating with financial advisors, and ensuring findings were structured to directly inform board-level decision-making.